Huaan Securities Co.Ltd(600909) 03 issued a research report on March 5, which said that Shenyang Xingqi Pharmaceutical Co.Ltd(300573) ( Shenyang Xingqi Pharmaceutical Co.Ltd(300573) .sz, latest price: 100.09 yuan) purchase rating was given for the first time. The reasons for rating mainly include: 1) deeply cultivate the eye medicine track for more than 40 years and build a Shenyang Xingqi Pharmaceutical Co.Ltd(300573) innovation leader; 2) 0.01% atropine eye drops: open up a new blue ocean of myopia drugs, and multi factors drive the growth momentum in the future; 3) 0.05% cyclosporine eye drops: it is the best choice for the treatment of dry eye disease and the first one approved for listing in China. Risk warning: drug promotion is less than expected risk; New drug R & D and approval risks; Pharmaceutical policy fluctuation risk.
© China Stock Market News